CD274 and non-small cell lung carcinoma: Although PD-L1 expression can be increased in these patients, ICIs should be avoided in these patients with NSCLC with driver oncogenes due to lack of efficacy and increased pulmonary and/or hepatic toxicity, either as single agents or in combination with TKIs [38,39,40].